Business Context and Reporting Period
This Form 8-K was filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on December 15, 2020, reporting events occurring on December 11, 2020. The company is an emerging growth company focused on hearing regeneration and remyelination programs. The filing details the entry into a material definitive agreement to secure funding for capital expansion and a planned relocation to a new facility in Lexington in 2021.
Key Financial Metrics
- Debt Financing: Entered into a Term Loan Facility with Silicon Valley Bank for a principal amount of $15.0 million.
- Interest Rate: The greater of (i) 1.50% plus the Prime Rate (with a zero floor) or (ii) 4.75%.
- Repayment Terms: Monthly interest-only payments through November 30, 2022. Principal and interest repaid in equal monthly installments thereafter through the maturity date of May 1, 2024.
- Final Payment: A mandatory final payment of $150,000 is due on the earliest of the maturity date, full prepayment, acceleration due to default, or termination.
- Collateral: Secured by substantially all company assets, excluding intellectual property.
- Liquidity Covenant: The company must maintain unrestricted cash with the Bank equal to the lesser of 100% of consolidated cash or 110% of outstanding obligations to the Bank.
Material Changes
The primary material change is the incurrence of $15.0 million in new debt. This financing is intended to support substantial capital expenditures and equipment purchases associated with the company's relocation and to drive forward its lead hearing program and pipeline. The filing does not provide comparative financial metrics (revenue, profit, or cash flow) for the prior period as this is a current report regarding a specific transaction rather than a periodic financial statement.
Guidance, Outlook, and Risks
Management Commentary: Management views the loan as capital-efficient given favorable interest rates, enabling the utilization of existing resources to prepare for potential pivotal trials in hearing.
Prepayment Penalties:
- 2.0% premium if prepaid within the first anniversary.
- 1.0% premium if prepaid between the first and second anniversary.
- 0.0% premium if prepaid after the second anniversary.
- Waived if refinanced by the Bank prior to maturity.
Risks and Contingencies: The agreement includes standard events of default, including insolvency, failure to pay, covenant breaches, material adverse changes, and money judgments exceeding $250,000. Upon default, the Bank may demand immediate repayment and exercise remedies against collateral.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Frequency Therapeutics, Inc., not Korro Bio, Inc.
- Confirm the impact of the 110% cash maintenance covenant on future liquidity flexibility.
- Review the full text of the Loan and Security Agreement (Exhibit 10.1) for specific affirmative and negative covenants.
- Monitor the company's progress on the 2021 relocation to Lexington and associated capital expenditures.
- Assess the company's ability to service debt given its status as an emerging growth company with no reported revenue in this filing.